Dabrafenib (4) (Tafinlar®) – Melanoma, BRAF V600 mutation, combination with trametinib, adjuvant therapy
Characteristics
| Start date | 01.10.2018 |
|---|---|
| Resolution | 22.03.2019 |
| Limitation date | 01.04.2024 limitation repealed |
| INN | Dabrafenib |
| Brand name | Tafinlar® |
| Pharm. company |
Dossier: Novartis Pharma GmbH
New distributor: NOVARTIS Pharma GmbH |
| G-BA procedure ID | 2018-10-01-D-383 |
| ATC code | L01XE23 |
| DDD | 0.3 g O |
| Therapeutic area | Oncological diseases |
| Reason for procedure | New Indication |
| Specialty | Special practice conditions |
| Indication (German) |
|---|
|
Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection. |
| Subpopulation | Indication | Comparator |
|---|---|---|
| Indicated in combination with trametinib for the adjuvant treatment of adult stage III melanoma patients with a BRAF V600 mutation after complete resection. | Observational waiting |
9. Associated procedures
<< List of all resolutions